# BridgeBio Pharma, Inc. (BBIO)

> Source: Nexqual · https://nexqual.com/BBIO · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, BridgeBio Pharma, Inc. (BBIO), nexqual.com/BBIO" · informational, not investment advice.

**Price:** USD 68.12 (+0.56% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 67.74 · day 67.07–69.32 · 52w 52.75–93.42 · market cap $13.3B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $713M, net income -$702M (-98.5% margin), free cash flow -$435M (SEC filings).
- 2 of 80 tracked superinvestors hold BBIO (13F, Q2 2026): 0 new, 0 added, 2 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 15 Form 4 filings, $48.6M; 0 not under a Rule 10b5-1 plan ($0K); 2 by opportunistic insiders (0 outside 10b5-1 plans), 6 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.83 on a 1–5 scale) (23 analysts), mean target USD 107.81 (range 80–156).
- Total return with dividends: 1Y +26.6% vs S&P 500 +14.9%; 5Y +44.9% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD -0.56, revenue estimate $296M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $69.7M | $77.6M | $9.3M | $222M | $502M | $713M |
| Gross profit | $66.6M | $74.2M | $6.9M | $218M | $481M | — |
| Operating income | -$577M | -$512M | -$607M | -$593M | -$523M | -$498M |
| Net income | -$586M | -$485M | -$653M | -$543M | -$733M | -$702M |
| EPS (diluted) | -$3.90 | -$3.26 | -$3.95 | -$2.88 | -$3.78 | — |
| Free cash flow | -$511M | -$424M | -$529M | -$522M | -$447M | -$435M |
| Gross margin | 95.5% | 95.6% | 73.7% | 98.3% | 95.8% | — |
| Operating margin | -827.1% | -659.6% | -6528.8% | -267.2% | -104.2% | -69.8% |
| Net margin | -841.2% | -624.2% | -7021.9% | -244.9% | -146.0% | -98.5% |
| Revenue growth | +745.1% | +11.4% | -88.0% | +2285.3% | +126.3% | — |
| Cash + short-term investments | $788M | $428M | $376M | $681M | $587M | — |
| Total debt | $431M | $431M | $446M | $437M | $2.01B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 18.7x · EV/Sales 21.4x · FCF yield -3.27% · Earnings yield -5.27% · Buyback yield (TTM) 1.58% · Net debt $1.93B · EV $15.2B

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold BBIO. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 2.11% | $741M | Reduced -16.0% |
| Polen Capital | Polen Capital Management | <0.01% | $298K | Reduced -91.3% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
15 of 15 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Kumar Neil | Chief Executive Officer | 10,000 | $691K | 0.2% | Yes (adopted May 13, 2026) | Routine (sold in Aug & Nov each year 2023–2025; this trade is outside those months) |
| 2026-08-18…2026-08-19 | Kumar Neil | Chief Executive Officer | 44,980 | $3.7M | 0.9% | Yes (adopted May 13, 2026) | Routine (sold in Aug & Nov each year 2023–2025) |
| 2026-07-30 | Apuli Maricel | Chief Accounting Officer | 2,000 | $160K | 1.5% | Yes (adopted September 8, 2025) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-09 | Ellis Andrea | Director | 17,167 | $1.4M | 43.2% | Yes (adopted December 3, 2025) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-09 | Cook Jennifer E. | Director | 148,589 | $13.2M | 94.7% | Yes (adopted March 16, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-23…2026-06-24 | Cook Jennifer E. | Director | 39,363 | $2.8M | 82.4% | Yes (adopted March 16, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22…2026-06-23 | Valantine Hannah | Director | 5,004 | $342K | 34.1% | Yes (adopted November 14, 2025) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-15 | Cook Jennifer E. | Director | 90,240 | $6.0M | 93.2% | Yes (adopted March 16, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-04…2026-06-05 | Kumar Neil | Chief Executive Officer | 80,000 | $5.4M | 1.6% | Yes (adopted March 31, 2025) | Routine (sold in Aug & Nov each year 2023–2025; this trade is outside those months) |
| 2026-05-21 | Kumar Neil | Chief Executive Officer | 26,103 | $1.8M | 0.5% | Yes (adopted March 31, 2025) | Routine (sold in Aug & Nov each year 2023–2025; this trade is outside those months) |
| 2026-05-18 | Trimarchi Thomas | President and CFO | 13,651 | $888K | 3.7% | Yes (adopted March 31, 2025) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-15 | Scott Randal W. | Director | 10,000 | $671K | 39.1% | Yes (adopted June 27, 2025) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-07…2026-05-08 | Kumar Neil | Chief Executive Officer | 80,000 | $5.4M | 1.5% | Yes (adopted March 31, 2025) | Routine (sold in Aug & Nov each year 2023–2025; this trade is outside those months) |
| 2026-04-30 | Apuli Maricel | Chief Accounting Officer | 2,000 | $143K | 1.5% | Yes (adopted September 8, 2025) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-04-09…2026-04-10 | Kumar Neil | Chief Executive Officer | 80,000 | $6.0M | 1.5% | Yes (adopted March 31, 2025) | Routine (sold in Aug & Nov each year 2023–2025; this trade is outside those months) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.83 on a 1–5 scale), 23 analysts; mean target USD 107.81 (low 80, high 156).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Morgan Stanley | Target lowered | Overweight | $97 → $87 |
| 2026-10-19 | Citigroup | Target lowered | Neutral | $94 → $91 |
| 2026-10-19 | Piper Sandler | Target raised | Overweight | $115 → $120 |
| 2026-10-07 | Barclays | Target lowered | Overweight | $157 → $156 |
| 2026-09-10 | HC Wainwright & Co. | Reiterated | Buy | $120 |
| 2026-09-02 | HC Wainwright & Co. | Reiterated | Buy | $120 |
| 2026-09-01 | Mizuho | Target raised | Outperform | $96 → $110 |
| 2026-08-12 | Truist Securities | Target raised | Buy | $102 → $107 |
| 2026-08-12 | Canaccord Genuity | Target raised | Buy | $104 → $106 |
| 2026-08-12 | JP Morgan | Target raised | Overweight | $100 → $111 |
| 2026-08-11 | B of A Securities | Target raised | Buy | $101 → $104 |
| 2026-08-11 | TD Cowen | Target raised | Buy | $95 → $110 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +26.6% | +44.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +26.7% | +7.7% |
| Volatility (annualized) | 46.5% | 76.3% |
| Max drawdown | -29.8% (Jul 2026→Oct 2026) | -87.6% (Nov 2021→May 2022) |

## Peers (Biotechnology)
JAZZ (Jazz Pharmaceuticals plc) USD 214.65 +1.26% · HALO (Halozyme Therapeutics, Inc.) USD 124.54 -0.23% · SMMT (Summit Therapeutics Inc.) USD 15.55 -1.77% · CORT (Corcept Therapeutics Incorporat) USD 107.5 -7.55% · TECH (Bio-Techne Corp) USD 72.62 -0.03% · ASND (Ascendis Pharma A/S) USD 242.99 +1.71%

## More
Full page: https://nexqual.com/BBIO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in BBIO's own 10-K filed 2026-02-24 (https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Alexion Pharma International Operations | "Eidos is also a party to a license agreement with Alexion Pharma International Operations Limited Company ("Alexion") pursuant to which we depend on Alexion for the commercialization of Beyonttra in Japan;" |
| Customer | SVB Securities | "Sales to, or through, Goldman Sachs and SVB by us under the ATM Agreement or otherwise pursuant to the registration statement could result in substantial dilution to the interests of other holders of our common stock." |
| Partner | Bayer | "We have licensed commercial rights in Europe to Bayer who are commercializing Beyonttra in all EU member states, the United Kingdom, Switzerland and Turkey under our Exclusive License Agreement with Bayer signed in March…" |
| Partner | Eidos Therapeutics | "Under the terms of the Eidos-Alexion License Agreement, Eidos granted Alexion an exclusive license to certain of our intellectual property rights to develop, manufacture and commercialize Beyonttra in Japan." |
| Partner | Novartis International Pharmaceutical | "We are also a party to a license agreement with Novartis International Pharmaceutical Ltd. for infigratinib under which we are required to use commercially reasonable efforts to develop infigratinib, and to obtain regula…" |
| Partner | BLUE OWL CAPITAL INC. (OWL) | "On January 17, 2024, we entered into a Financing Agreement with each of the guarantors, which was amended on February 12, 2024 (the "Financing Agreement") and June 20, 2024 (the Financing Agreement, as amended by the Sec…" |
| Partner | Kyowa Kirin | "We determined that the KKC License Agreement falls within the scope of ASC 606 as Kyowa Kirin is a customer in this arrangement, and we identified the following performance obligations in the agreement:" |
| Partner | Navire Pharma | "For the years ended December 31, 2024 and 2023, we recognized $9.9 million and $7.4 million, respectively, in license and services revenue relating to the Navire-BMS License Agreement." |
| Competitor | Pfizer (PFE) | "Attruby/Beyonttra (acoramidis) for the treatment of adults with ATTR-CM competes with Vyndaqel / Vyndamax (tafamidis meglumine / tafamidis), which is a commercial product marketed by Pfizer, Inc. and approved in certain …" |

Other companies that name BBIO in their own reports (relationship from BBIO's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| related | BridgeBio Oncology Therapeutics, Inc. (BBOT) | 10-K 2026-03-05 | "BridgeBio Pharma and its controlled entities are related parties of BBOT." |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Net product revenue | $222.4M | 91.3% | +211.1% |
| Royalty revenue | $15.4M | 6.3% | +850.2% |
| License and services revenue | $5.8M | 2.4% | -84.5% |
| Total revenue | $243.7M | 100% | — |

## Customer concentration

Period ended 2026-06-30: 28.8%, 18.8%, 18%, 15%, 13.2% of revenue from unnamed direct customers (10-Q, filed 2026-08-10).

## Company outlook (8-K filed 2026-08-10)

- "An update of the Phase 2 program in hypochondroplasia is expected in the second half of 2026."
- "Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.56 | $-0.45 | +23.4% | $295.8M | 6 |
| Next quarter (ends 2026-12-31) | $-0.40 | $-0.25 | +58.7% | $306.6M | 5 |
| Current fiscal year (ends 2026-12-31) | $-2.62 | $-2.14 | +22.3% | $1.04B | 8 |
| Next fiscal year (ends 2027-12-31) | $-0.22 | $0.59 | -138.1% | $1.67B | 6 |